Acrigen Biosciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Acrigen Biosciences, Inc. - overview
Established
2019
Location
Alameda, CA, US
Primary Industry
Biotechnology
About
Based in CA, US, and founded in 2019, Acrigen Biosciences, Inc. provides a pipeline of therapies to treat genetic disorders. In March 2022, the firm received USD 1 million from investor The National Science Foundation. The company develops Precision Gene Editing Systems which harness the power of CRISPR which is used in human therapeutics.
Utilizing ErAcrs (engineered anti-CRISPR proteins) and revolutionary αCas and μCas CRISPR gene editors, Acrigen's unique technology develops an editing toolkit.
Current Investors
Alexandria Venture Investments, Dolby Family Ventures, Berkeley Catalyst Fund
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.acrigen.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Acrigen Biosciences, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.